The Strategic Timing of Antiretroviral Treatment (START) study showed that immediate initiation of cART with a CD4+ T-cell count >500 cells/mm3 led to lower rates of serious AIDS-related and non-AIDS-related illnesses and death compared to deferring cART until the CD4 count reached 350 cells/mm3 [5]. This evidence concerns the gene CD4 and AIDS.